The pharmacokinetics of cefoperazone were evaluated in 25 infants (mean age, 26 days) after intramuscular and intravenous routes of administration. The levels in blood that were achieved were severalfold higher than those required to inhibit common pathogens. The mean half-life of 240 min was one-half of that observed in 1-to 2-day-old infants but about twice that seen in adults. Further evaluation is needed to study the efficacy of the drug in infants and children.
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Cefoperazone (CPZ) is a new semisynthetic third-generation cephalosporin antibiotic with a broad antimicrobial spectrum which includes Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, ampicillin-resistant Haemophilus influenzae, and Streptococcus agalactiae or group B streptococcus in addition to other common gramnegative and gram-positive pathogens (3, 7, 9) . It has a longer half-life than other third-generation cephalosporins (8) and crosses the blood brain barrier in therapeutic concentrations (4, 5) . Studies in adults have revealed CPZ to be useful in various bacterial infections (6, 10) , including meningitis (5). In the pediatric age group, including neonates, the drug has not been well studied. Single doses administered during the first week of life were safe and revealed a prolonged half-life (11) . We now report the pharmacokinetics of this drug in infants older than 2 weeks.
( Table 1 ). An additional specimen was collected just before the dose in the i.m. groups and at the end of infusion in the i.v. groups. Serum was separated immediately and kept frozen at -20°C. The specimens were shipped in dry ice within 2 to 6 weeks of collection to the University of Tennessee, where they were received in a frozen state. The concentration of CPZ was determined by high-performance liquid chromatography by using a Water's Associates HPLC system with a model 440, 254-fixed-wave-length detector and a Bondapak C-18 column (10 ,um by 13.9 mm by 30 cm). Samples were run isocratically with hydrochlorothiazide as an internal standard. The serum half-life (tl,2) and volume of distribution were determined by plotting the serum concentration against time by using a semilogarithmic graph as previously described (11). The t, was calculated when the level in blood was declining exponentially during the elimination phase by utilizing the formula tl,2 = In 21k where k is the elimination rate constant, These studies indicate the CPZ was quickly absorbed after the i.m. dose and achieved levels in blood comparable to those obtained with i.v. infusions. Levels in blood during 15 to 30 min after the dose were 12 to 100 times the MIC for 90% of the strains of common pathogens, including Escherichia coli and Proteus mirabilis (9) and 17 to 30 times more than necessary to inhibit 90% of the strains of Staphylococcus aureus (9) . Levels in blood observed in this study were lower than those reported in 1-to 2-day-old infants, including premature infants (11) . This difference may be due to a larger dose (50 mg/kg) and also immature renal and liver functions at that age, as CPZ is excreted both by the renal and biliary tracts. This is also reflected in a very prolonged t2 of almost 7 to 8 h in 1-to 2-day-old infants (11) compared with ca. 3 to 4 h (Table 2) in the present study. The tw in the present study is about twice as long as that reported in adults (1) and is consistent with administration every 12 h in this age group of infants. The result of this and other studies suggest that CPZ may be further evaluated in newborn infants with various bacterial infections.
